{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T15:15:09Z","timestamp":1793459709714,"version":"4.5.0"},"reference-count":48,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["K76AG074919"],"award-info":[{"award-number":["K76AG074919"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["K76AG083304"],"award-info":[{"award-number":["K76AG083304"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Alzheimer\u2019s Disease"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>People with Alzheimer's disease (AD) now have access to disease-modifying treatment with anti-amyloid monoclonal antibodies (mAbs). Their perception of risks and benefits and approach to treatment decisions remain unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>We aimed to understand how people with AD weigh the benefits and costs of anti amyloid mAbs and incorporate these into decisions about treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted semi-structured interviews with people with biomarker- or imaging-confirmed AD and mild or moderate cognitive impairment who were seen at memory care clinics and discussed lecanemab with a clinician. Interviews were recorded, transcribed, and deidentified. Thematic analysis identified themes and subthemes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 22 participants (mean age 70, 8 [36%] women, 22 [100%] White), analysis revealed 3 major themes and associated subthemes: (1) People with AD sought and obtained information from different sources\u2014advocacy organizations, the Internet, and clinicians; (2) Hopes, expected benefits, and the existential threat of dementia drove willingness and readiness to start lecanemab; (3) Individual traits, family factors, and degree of trust in expertise influenced how people balanced risks and benefits. Some would accept treatment at any cost; others carefully weighed risks and burdens, but were motivated by supportive families, insurance coverage, and trust in expertise; for a few, costs decidedly outweighed their personal benefits. People with AD desired more individualized information and to hear more from patients who took the medication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Results from this first qualitative study of people with AD considering treatment with anti-amyloid mAbs can inform clinician, health system and policy efforts to individualize decisions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/13872877251329519","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T06:50:12Z","timestamp":1744267812000},"page":"494-504","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":15,"title":["A qualitative study of people with Alzheimer\u2019s disease in a memory clinic considering lecanemab treatment"],"prefix":"10.1177","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1377-5406","authenticated-orcid":false,"given":"Anna L","family":"Parks","sequence":"first","affiliation":[{"name":"Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8918-2418","authenticated-orcid":false,"given":"Ayush","family":"Thacker","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Mongan Institute Center for Aging and Serious Illness, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7052-1288","authenticated-orcid":false,"given":"Daniel","family":"Dohan","sequence":"additional","affiliation":[{"name":"University of California San Francisco, Institute for Health Policy Studies, San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8869-3240","authenticated-orcid":false,"given":"Liliana A Ramirez","family":"Gomez","sequence":"additional","affiliation":[{"name":"Memory Disorders Division, Department of Neurology, Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4881-9416","authenticated-orcid":false,"given":"Christine S","family":"Ritchie","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Mongan Institute Center for Aging and Serious Illness, Boston, MA, USA"},{"name":"Division of Palliative Care and Geriatric Medicine, Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9324-1943","authenticated-orcid":false,"given":"Joanna","family":"Paladino","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Mongan Institute Center for Aging and Serious Illness, Boston, MA, USA"},{"name":"Division of Palliative Care and Geriatric Medicine, Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8400-6888","authenticated-orcid":false,"given":"Sachin J","family":"Shah","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Mongan Institute Center for Aging and Serious Illness, Boston, MA, USA"},{"name":"Division of General Internal Medicine, Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-023-01405-0"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.05.2351"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.2991"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.30"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2023.1749"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.11701"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.7326\/M23-3377"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.18652"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X14551638"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X20911870"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/intqhc\/mzm042"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/nhs.12048"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1191\/1478088706qp063oa"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/1049732315617444"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1177\/1049732316665344"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1080\/08870440903194015"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-215203"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-220536"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001331"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.121795"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1177\/1471301219862439"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269216318809571"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1080\/13607863.2018.1544212"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/gps.5628"},{"key":"e_1_3_5_27_2","unstructured":"Research T. Real-world prescribing of lecanemab in the United States. Truveta https:\/\/www.truveta.com\/blog\/research\/ispor-2024-lecanemab\/ (2024 accessed 9 October 2024)."},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.2202\/1538-0645.1395"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1086\/428914"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1177\/0022146510383498"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.6016"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2021.0238"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.19747"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1109283"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-022-07768-y"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0292"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3102"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.24.2313"},{"key":"e_1_3_5_39_2","unstructured":"Allen A. The real costs of the new Alzheimer\u2019s drug Leqembi\u2014and why taxpayers will foot much of the bill \u2013 CBS News https:\/\/www.cbsnews.com\/news\/alzheimers-drug-leqembi-cost-patients-taxpayers\/ (2023 accessed 12 June 2024)."},{"key":"e_1_3_5_40_2","unstructured":"Leqembi and Alzheimer\u2019s: What to Know About the New Drug Treatment and Benefits \u2013 The New York Times https:\/\/www.nytimes.com\/2024\/06\/10\/well\/mind\/alzheimers-treatment-leqembi.html (accessed 12 June 2024)."},{"key":"e_1_3_5_41_2","unstructured":"Hamilton J. An experimental Alzheimer\u2019s drug outperforms one just approved by the FDA. NPR 17 July 2023 https:\/\/www.npr.org\/sections\/health-shots\/2023\/07\/17\/1188075646\/donanemab-experimental-alzheimers-drug-outperforms-lecanemab-leqembi (17 July 2023 accessed 12 June 2024)."},{"key":"e_1_3_5_42_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.19320"},{"key":"e_1_3_5_43_2","doi-asserted-by":"publisher","DOI":"10.1080\/10810730.2019.1606364"},{"key":"e_1_3_5_44_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-005434"},{"key":"e_1_3_5_45_2","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.19.00256"},{"key":"e_1_3_5_46_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.6196"},{"key":"e_1_3_5_47_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.300.14.1665"},{"key":"e_1_3_5_48_2","article-title":"Shared decision making in the care of patients with cancer","volume":"43","author":"Shickh S","year":"2023","unstructured":"Shickh S, Leventakos K, Lewis MA, et al. Shared decision making in the care of patients with cancer. Am Soc Clin Oncol Educ Book 2023; 43: e389516.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"e_1_3_5_49_2","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2015.006171"}],"container-title":["Journal of Alzheimer\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13872877251329519","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13872877251329519","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13872877251329519","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:10:18Z","timestamp":1777371018000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13872877251329519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1177\/13872877251329519"],"URL":"https:\/\/doi.org\/10.1177\/13872877251329519","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.09.17.24313315","asserted-by":"object"}]},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,10]]}}}